Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Surgery. 2010 Apr;147(4):481-90. doi: 10.1016/j.surg.2009.10.037. Epub 2009 Dec 11.
The Leapfrog Group aims to improve surgical outcomes through promoting hospital adoption of procedure-specific process measures, although it is unclear whether compliance reflects a hospital's overall quality. The purpose of this study was to evaluate whether implementation of Leapfrog's standard for routine beta-blockade was associated with reductions in mortality after open abdominal aortic aneurysm (AAA) repair alone versus other high-risk operations.
Using a 2:1 matched case-control study design, hospitals that had not adopted the beta-blockade standard (n = 72) were compared with hospitals that had implemented this Leapfrog standard (n = 36). Leapfrog survey data were linked to patient outcomes in the California OSHPD database from 2000 to 2005. Random-effects Poisson regression models were used to evaluate in-hospital mortality over time for patients undergoing AAA repair versus esophagectomy, hepatectomy, pancreatectomy, colectomy, gastrectomy, and pulmonary lobectomy.
A total of 6,199 AAA repairs, 2,780 esophagectomies, 2,544 hepatectomies, 2,909 pancreatectomies, 57,795 colectomies, 6,267 gastrectomies, and 10,210 lobectomies were analyzed. AAA-associated mortality significantly declined in hospitals that adopted the beta-blocker standard (relative risk [RR]: 0.49; 95% confidence interval [CI]: 0.24-0.97; P < .05). Implementation of this Leapfrog standard had no effect on reducing adjusted mortality rates for other high-risk operations, including esophagectomy (RR: 0.70; 95% CI: 0.25-1.89), hepatectomy (RR: 1.16; 95% CI: 0.32-4.29), pancreatectomy (RR: 0.76; 95% CI: 0.28-2.02), colectomy (RR: 1.12; 95% CI: 0.86-1.44), gastrectomy (RR: 1.17; 95% CI: 0.57-2.43), and lobectomy (RR: 0.98; 95% CI: 0.46-2.08) (all P > .05).
Compliance with peri-operative beta-blockade resulted in a significant reduction in mortality after open AAA repair over time, but it had no crossover effect on mortality associated with other high-risk operations in the same hospital. These data suggest that improvements in outcomes resulting from the adoption of evidence-based process measures are procedure specific and do not necessarily reflect overall hospital quality.
Leapfrog 集团旨在通过推广医院采用特定手术流程的措施来改善手术结果,尽管尚不清楚遵守规定是否反映了医院的整体质量。本研究的目的是评估常规β受体阻滞剂应用是否与开腹腹主动脉瘤(AAA)修复术的死亡率降低有关,而与其他高危手术无关。
使用 2:1 匹配的病例对照研究设计,将未采用β受体阻滞剂标准的医院(n = 72)与已采用 Leapfrog 标准的医院(n = 36)进行比较。将 Leapfrog 调查数据与 2000 年至 2005 年加利福尼亚 OSHPD 数据库中的患者结局相关联。使用随机效应泊松回归模型评估接受 AAA 修复术与食管切除术、肝切除术、胰切除术、结肠切除术、胃切除术和肺叶切除术患者的住院死亡率随时间的变化。
共分析了 6199 例 AAA 修复术、2780 例食管切除术、2544 例肝切除术、2909 例胰切除术、57795 例结肠切除术、6267 例胃切除术和 10210 例肺叶切除术。AAA 相关死亡率在采用β阻滞剂标准的医院显著下降(相对风险 [RR]:0.49;95%置信区间 [CI]:0.24-0.97;P <.05)。实施这一 Leapfrog 标准对降低其他高危手术(包括食管切除术、肝切除术、胰切除术、结肠切除术、胃切除术和肺叶切除术)的调整死亡率没有影响,RR:0.70;95%CI:0.25-1.89),肝切除术(RR:1.16;95%CI:0.32-4.29),胰切除术(RR:0.76;95%CI:0.28-2.02),结肠切除术(RR:1.12;95%CI:0.86-1.44),胃切除术(RR:1.17;95%CI:0.57-2.43)和肺叶切除术(RR:0.98;95%CI:0.46-2.08)(所有 P >.05)。
围手术期β受体阻滞剂的应用导致开腹 AAA 修复术后死亡率随时间显著降低,但对同一医院其他高危手术的死亡率无交叉影响。这些数据表明,采用循证流程措施所带来的结果改善是特定于手术的,不一定反映医院的整体质量。